Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CNK vs RGC vs NUVB vs AMC vs IMAX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CNK
Cinemark Holdings, Inc.

Entertainment

Communication ServicesNYSE • US
Market Cap$3.21B
5Y Perf.+76.9%
RGC
Regencell Bioscience Holdings Limited

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • HK
Market Cap$15.56B
5Y Perf.+12941.9%
NUVB
Nuvation Bio Inc.

Biotechnology

HealthcareNYSE • US
Market Cap$1.67B
5Y Perf.-44.2%
AMC
AMC Entertainment Holdings, Inc.

Entertainment

Communication ServicesNYSE • US
Market Cap$930M
5Y Perf.-99.6%
IMAX
IMAX Corporation

Entertainment

Communication ServicesNYSE • CA
Market Cap$1.92B
5Y Perf.+120.8%

CNK vs RGC vs NUVB vs AMC vs IMAX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CNK logoCNK
RGC logoRGC
NUVB logoNUVB
AMC logoAMC
IMAX logoIMAX
IndustryEntertainmentDrug Manufacturers - Specialty & GenericBiotechnologyEntertainmentEntertainment
Market Cap$3.21B$15.56B$1.67B$930M$1.92B
Revenue (TTM)$3.12B$0.00$143M$5.03B$405M
Net Income (TTM)$138M$-5M$-146M$-547M$43M
Gross Margin40.7%91.6%75.3%58.1%
Operating Margin11.0%-105.0%46.5%21.4%
Forward P/E13.0x21.1x
Total Debt$3.78B$86K$10M$8.14B$297M
Cash & Equiv.$344M$3M$164M$429M$151M

CNK vs RGC vs NUVB vs AMC vs IMAXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CNK
RGC
NUVB
AMC
IMAX
StockJul 21May 26Return
Cinemark Holdings, … (CNK)100176.9+76.9%
Regencell Bioscienc… (RGC)10013041.9+12941.9%
Nuvation Bio Inc. (NUVB)10055.8-44.2%
AMC Entertainment H… (AMC)1000.4-99.6%
IMAX Corporation (IMAX)100220.8+120.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: CNK vs RGC vs NUVB vs AMC vs IMAX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CNK leads in 3 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. IMAX Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. RGC and NUVB also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CNK
Cinemark Holdings, Inc.
The Value Play

CNK carries the broadest edge in this set and is the clearest fit for value and stability.

  • Better valuation composite
  • Beta 0.22 vs NUVB's 2.04
  • 1.1% yield; the other 4 pay no meaningful dividend
Best for: value and stability
RGC
Regencell Bioscience Holdings Limited
The Long-Run Compounder

RGC ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.

  • 119.3% 10Y total return vs IMAX's 8.9%
  • Lower volatility, beta 0.72, Low D/E 1.0%, current ratio 41.92x
  • Beta 0.72, current ratio 41.92x
  • +5.3% vs AMC's -43.9%
Best for: long-term compounding and sleep-well-at-night
NUVB
Nuvation Bio Inc.
The Growth Play

NUVB is the clearest fit if your priority is growth exposure.

  • Rev growth 7.0%, EPS growth 71.6%
  • 7.0% revenue growth vs CNK's 2.1%
Best for: growth exposure
AMC
AMC Entertainment Holdings, Inc.
The Communication Services Pick

Among these 5 stocks, AMC doesn't own a clear edge in any measured category.

Best for: communication services exposure
IMAX
IMAX Corporation
The Income Pick

IMAX is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 1 yrs, beta 0.43
  • 10.7% margin vs NUVB's -102.1%
  • 4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8%
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthNUVB logoNUVB7.0% revenue growth vs CNK's 2.1%
ValueCNK logoCNKBetter valuation composite
Quality / MarginsIMAX logoIMAX10.7% margin vs NUVB's -102.1%
Stability / SafetyCNK logoCNKBeta 0.22 vs NUVB's 2.04
DividendsCNK logoCNK1.1% yield; the other 4 pay no meaningful dividend
Momentum (1Y)RGC logoRGC+5.3% vs AMC's -43.9%
Efficiency (ROA)IMAX logoIMAX4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8%

CNK vs RGC vs NUVB vs AMC vs IMAX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CNKCinemark Holdings, Inc.
FY 2025
Admissions Revenue
49.6%$1.5B
Concessions
39.4%$1.2B
Other Revenues
11.0%$343M
RGCRegencell Bioscience Holdings Limited

Segment breakdown not available.

NUVBNuvation Bio Inc.
FY 2025
License
60.8%$38M
Product
39.2%$25M
AMCAMC Entertainment Holdings, Inc.
FY 2025
Admission
49.4%$2.7B
Food and Beverage
31.1%$1.7B
Total Other Product And Service
9.8%$525M
Product and Service, Other
6.9%$373M
Advertising
2.8%$152M
IMAXIMAX Corporation
FY 2025
Image Enhancement And Maintenance Services
54.7%$218M
Technology Sales
24.7%$98M
Technology Rentals
20.6%$82M

CNK vs RGC vs NUVB vs AMC vs IMAX — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIMAXLAGGINGAMC

Income & Cash Flow (Last 12 Months)

NUVB leads this category, winning 3 of 6 comparable metrics.

AMC and RGC operate at a comparable scale, with $5.0B and $0 in trailing revenue. IMAX is the more profitable business, keeping 10.7% of every revenue dollar as net income compared to NUVB's -102.1%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
RevenueTrailing 12 months$3.1B$0$143M$5.0B$405M
EBITDAEarnings before interest/tax$545M-$4M-$145M$2.6B$150M
Net IncomeAfter-tax profit$138M-$5M-$146M-$547M$43M
Free Cash FlowCash after capex$177M-$7M-$126M-$124M$115M
Gross MarginGross profit ÷ Revenue+40.7%+91.6%+75.3%+58.1%
Operating MarginEBIT ÷ Revenue+11.0%-105.0%+46.5%+21.4%
Net MarginNet income ÷ Revenue+4.4%-102.1%-10.9%+10.7%
FCF MarginFCF ÷ Revenue+5.7%-88.1%-2.5%+28.5%
Rev. Growth (YoY)Latest quarter vs prior year-4.7%+26.0%+21.2%-6.1%
EPS Growth (YoY)Latest quarter vs prior year-18.2%+106.3%+53.2%+65.5%
NUVB leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — AMC and IMAX each lead in 2 of 6 comparable metrics.

At 26.4x trailing earnings, CNK trades at a 53% valuation discount to IMAX's 56.6x P/E. On an enterprise value basis, AMC's 4.7x EV/EBITDA is more attractive than IMAX's 13.1x.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
Market CapShares × price$3.2B$15.6B$1.7B$930M$1.9B
Enterprise ValueMkt cap + debt − cash$6.6B$15.6B$1.5B$8.6B$2.1B
Trailing P/EPrice ÷ TTM EPS26.42x-3617.24x-8.03x-1.24x56.56x
Forward P/EPrice ÷ next-FY EPS est.12.97x21.15x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple12.23x4.67x13.10x
Price / SalesMarket cap ÷ Revenue1.03x26.61x0.19x4.69x
Price / BookPrice ÷ Book value/share8.92x1893.39x5.38x4.63x
Price / FCFMarket cap ÷ FCF18.11x16.18x
Evenly matched — AMC and IMAX each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

IMAX leads this category, winning 3 of 9 comparable metrics.

CNK delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-67 for RGC. RGC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNK's 9.14x. On the Piotroski fundamental quality scale (0–9), IMAX scores 7/9 vs AMC's 3/9, reflecting strong financial health.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
ROE (TTM)Return on equity+25.4%-67.0%-44.1%+10.8%
ROA (TTM)Return on assets+3.0%-60.2%-23.8%-6.9%+4.9%
ROICReturn on invested capital+7.5%-43.8%-54.3%+23.7%+12.7%
ROCEReturn on capital employed+9.3%-46.8%-42.8%+29.0%+14.5%
Piotroski ScoreFundamental quality 0–954437
Debt / EquityFinancial leverage9.14x0.01x0.03x0.70x
Net DebtTotal debt minus cash$3.4B-$3M-$154M$7.7B$146M
Cash & Equiv.Liquid assets$344M$3M$164M$429M$151M
Total DebtShort + long-term debt$3.8B$85,741$10M$8.1B$297M
Interest CoverageEBIT ÷ Interest expense1.89x-162.11x0.35x21.15x
IMAX leads this category, winning 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RGC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in RGC five years ago would be worth $1,138,979 today (with dividends reinvested), compared to $160 for AMC. Over the past 12 months, RGC leads with a +529.4% total return vs AMC's -43.9%. The 3-year compound annual growth rate (CAGR) favors RGC at 2.6% vs AMC's -70.5% — a key indicator of consistent wealth creation.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
YTD ReturnYear-to-date+17.2%+53.2%-43.8%-5.6%-1.1%
1-Year ReturnPast 12 months-10.7%+529.4%+136.3%-43.9%+38.9%
3-Year ReturnCumulative with dividends+71.0%+4525.9%+197.5%-97.4%+79.5%
5-Year ReturnCumulative with dividends+29.3%+11289.8%-58.3%-98.4%+70.3%
10-Year ReturnCumulative with dividends-6.6%+11926.8%-51.8%-84.7%+8.9%
CAGR (3Y)Annualised 3-year return+19.6%+2.6%+43.8%-70.5%+21.5%
RGC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CNK and IMAX each lead in 1 of 2 comparable metrics.

CNK is the less volatile stock with a 0.22 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMAX currently trades 82.6% from its 52-week high vs AMC's 37.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
Beta (5Y)Sensitivity to S&P 5000.22x0.72x2.04x1.82x0.43x
52-Week HighHighest price in past year$34.01$83.60$9.75$4.08$43.16
52-Week LowLowest price in past year$21.60$3.93$1.57$0.93$24.20
% of 52W HighCurrent price vs 52-week peak+80.8%+37.6%+49.4%+37.3%+82.6%
RSI (14)Momentum oscillator 0–10043.747.559.160.042.4
Avg Volume (50D)Average daily shares traded2.1M139K4.3M30.1M1.1M
Evenly matched — CNK and IMAX each lead in 1 of 2 comparable metrics.

Analyst Outlook

IMAX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: CNK as "Buy", RGC as "Hold", NUVB as "Buy", AMC as "Hold", IMAX as "Buy". Consensus price targets imply 157.3% upside for NUVB (target: $12) vs 15.2% for CNK (target: $32). CNK is the only dividend payer here at 1.05% yield — a key consideration for income-focused portfolios.

MetricCNK logoCNKCinemark Holdings…RGC logoRGCRegencell Bioscie…NUVB logoNUVBNuvation Bio Inc.AMC logoAMCAMC Entertainment…IMAX logoIMAXIMAX Corporation
Analyst RatingConsensus buy/hold/sellBuyHoldBuyHoldBuy
Price TargetConsensus 12-month target$31.67$12.40$2.00$43.00
# AnalystsCovering analysts31492825
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises001
Dividend / ShareAnnual DPS$0.29
Buyback YieldShare repurchases ÷ mkt cap+8.6%0.0%0.0%0.0%+0.1%
IMAX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

IMAX leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). NUVB leads in 1 (Income & Cash Flow). 2 tied.

Best OverallIMAX Corporation (IMAX)Leads 2 of 6 categories
Loading custom metrics...

CNK vs RGC vs NUVB vs AMC vs IMAX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CNK or RGC or NUVB or AMC or IMAX a better buy right now?

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 2. 1% for Cinemark Holdings, Inc. (CNK). Cinemark Holdings, Inc. (CNK) offers the better valuation at 26. 4x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate Cinemark Holdings, Inc. (CNK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CNK or RGC or NUVB or AMC or IMAX?

On trailing P/E, Cinemark Holdings, Inc.

(CNK) is the cheapest at 26. 4x versus IMAX Corporation at 56. 6x. On forward P/E, Cinemark Holdings, Inc. is actually cheaper at 13. 0x.

03

Which is the better long-term investment — CNK or RGC or NUVB or AMC or IMAX?

Over the past 5 years, Regencell Bioscience Holdings Limited (RGC) delivered a total return of +112.

9%, compared to -98. 4% for AMC Entertainment Holdings, Inc. (AMC). Over 10 years, the gap is even starker: RGC returned +119. 3% versus AMC's -84. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CNK or RGC or NUVB or AMC or IMAX?

By beta (market sensitivity over 5 years), Cinemark Holdings, Inc.

(CNK) is the lower-risk stock at 0. 22β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 836% more volatile than CNK relative to the S&P 500. On balance sheet safety, Regencell Bioscience Holdings Limited (RGC) carries a lower debt/equity ratio of 1% versus 9% for Cinemark Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CNK or RGC or NUVB or AMC or IMAX?

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 2. 1% for Cinemark Holdings, Inc. (CNK). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -49. 5% for Cinemark Holdings, Inc.. Over a 3-year CAGR, IMAX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CNK or RGC or NUVB or AMC or IMAX?

IMAX Corporation (IMAX) is the more profitable company, earning 8.

5% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMC leads at 38. 1% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CNK or RGC or NUVB or AMC or IMAX more undervalued right now?

On forward earnings alone, Cinemark Holdings, Inc.

(CNK) trades at 13. 0x forward P/E versus 21. 1x for IMAX Corporation — 8. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.

08

Which pays a better dividend — CNK or RGC or NUVB or AMC or IMAX?

In this comparison, CNK (1.

1% yield) pays a dividend. RGC, NUVB, AMC, IMAX do not pay a meaningful dividend and should not be held primarily for income.

09

Is CNK or RGC or NUVB or AMC or IMAX better for a retirement portfolio?

For long-horizon retirement investors, Cinemark Holdings, Inc.

(CNK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 22), 1. 1% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNK: -6. 6%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CNK and RGC and NUVB and AMC and IMAX?

These companies operate in different sectors (CNK (Communication Services) and RGC (Healthcare) and NUVB (Healthcare) and AMC (Communication Services) and IMAX (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CNK is a small-cap quality compounder stock; RGC is a mid-cap quality compounder stock; NUVB is a small-cap high-growth stock; AMC is a small-cap quality compounder stock; IMAX is a small-cap high-growth stock. CNK pays a dividend while RGC, NUVB, AMC, IMAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CNK

Stable Dividend Mega-Cap

  • Sector: Communication Services
  • Market Cap > $100B
  • Gross Margin > 24%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

RGC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

NUVB

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 1299%
  • Gross Margin > 54%
Run This Screen
Stocks Like

AMC

High-Growth Disruptor

  • Sector: Communication Services
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 45%
Run This Screen
Stocks Like

IMAX

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Net Margin > 6%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.